MYC and plasma cell myeloma: Combining the results from the genomic and transcriptomic analyses across all different somatic events spontaneously acquired during Vk*MYC myeloma pathogenesis, we noted the convergence of acquired mutations on pathways activating NFkB (38%), RAS/mTORC1 (27%), cell cycle (48%) and chromatin modifiers (67%) as observed in human MM (Fig. 5A)13.